Recent

% | $
Quotes you view appear here for quick access.

Delcath Systems, Inc. Message Board

  • okiedivot okiedivot Feb 27, 2013 8:11 AM Flag

    May 2nd it is.

    An FDA advisory panel will review on May 2 Delcath's (DCTH) application for using its Hepatic Delivery System and melphalan hydrochloride to treat patients with unresectable ocular melanoma that is metastatic to the liver. Shares are +2.7% but down from earlier highs. (PR)

 
DCTH
0.310.00(0.00%)May 27 3:58 PMEDT